{"id":275958,"date":"2025-10-04T01:28:39","date_gmt":"2025-10-04T01:28:39","guid":{"rendered":"https:\/\/www.europesays.com\/us\/275958\/"},"modified":"2025-10-04T01:28:39","modified_gmt":"2025-10-04T01:28:39","slug":"cgtlives-weekly-rewind-october-3-2025","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/275958\/","title":{"rendered":"CGTLive\u00ae\u2019s Weekly Rewind \u2013 October 3, 2025"},"content":{"rendered":"\n<p class=\"\">Welcome to CGTLive\u00ae\u2019s Weekly Rewind! We\u2019ve compiled 5 highlights from this week\u2019s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.<\/p>\n<p><a href=\"https:\/\/www.cgtlive.com\/view\/mavrix-bio-angelman-syndrome-gene-therapy-mvx-220-garners-fda-fast-track-designation\" rel=\"noreferrer noopener\" target=\"_blank\">1. MavriX Bio\u2019s Angelman Syndrome Gene Therapy MVX-220 Garners FDA Fast Track Designation<\/a><\/p>\n<p class=\"\">MVX-220 is intended to provide a functional copy of UBE3A, the disease-targeted gene, to the neurons.<\/p>\n<p><a href=\"https:\/\/www.cgtlive.com\/view\/world-heart-day-2025-looking-recent-progress-cardiology-cell-gene-therapy\" rel=\"noreferrer noopener\" target=\"_blank\">2. World Heart Day 2025: Looking Back at Recent Progress in Cardiology Cell and Gene Therapy<\/a><\/p>\n<p class=\"\">In observance of World Heart Day, held annually on September 29, we took a look back at news in cell\/gene therapy for cardiovascular disease from the past few months.<\/p>\n<p><a href=\"https:\/\/www.cgtlive.com\/view\/fda-publishes-new-draft-guidance-industry-documents-aimed-cell-gene-therapy-development\" rel=\"noreferrer noopener\" target=\"_blank\">3. FDA Publishes 3 New Draft Guidance for Industry Documents Aimed at Cell and Gene Therapy Development<\/a><\/p>\n<p class=\"\">The documents cover topics including efficient trial design, expedited review programs, and postapproval data collection.<\/p>\n<p><a href=\"https:\/\/www.cgtlive.com\/view\/cdkl5-gene-therapy\" rel=\"noreferrer noopener\" target=\"_blank\">4. CDKL5 and Gene Therapy<\/a><\/p>\n<p class=\"\">CGTLive\u00ae interviewed Jainu Jogani, the cofounder of Child\u2019s Cure Genetic Research, whose daughter Reyna has CDKL5 deficiency disorder (CDKL5).<\/p>\n<p><a href=\"https:\/\/www.cgtlive.com\/view\/umoja-biopharma-in-situ-car-t-therapy-ub-vv111-fast-tracked-several-b-cell-malignancy-indications\" rel=\"noreferrer noopener\" target=\"_blank\">5. Umoja Biopharma&#8217;s In Situ CAR-T Therapy UB-VV111 Fast Tracked for Several R\/R B-Cell Malignancy Indications<\/a><\/p>\n<p class=\"\">UB-VV111 is currently being evaluated in a phase 1 clinical trial for adult patients with r\/r CD19+ B-cell malignancies.<\/p>\n","protected":false},"excerpt":{"rendered":"Welcome to CGTLive\u00ae\u2019s Weekly Rewind! We\u2019ve compiled 5 highlights from this week\u2019s coverage of advances in gene and&hellip;\n","protected":false},"author":3,"featured_media":258381,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[26],"tags":[815,159,67,132,68],"class_list":{"0":"post-275958","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-genetics","8":"tag-genetics","9":"tag-science","10":"tag-united-states","11":"tag-unitedstates","12":"tag-us"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/115313305334068298","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/275958","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=275958"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/275958\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/258381"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=275958"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=275958"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=275958"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}